 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...209210211212213214215216217218219...235236» |
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Mar 14, 2015
P3, N=200, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2014 --> Apr 2015
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Trial initiation date, Trial withdrawal, Metastases: Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Mar 14, 2015
P2, N=0, Withdrawn, Sponsor: University of Southern California
Trial primary completion date: Dec 2014 --> Apr 2015 N=58 --> 0 | Initiation date: Sep 2014 --> Mar 2015 | Not yet recruiting --> Withdrawn
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - Mar 14, 2015
P3, N=900, Active, not recruiting, Sponsor: Sanofi
N=58 --> 0 | Initiation date: Sep 2014 --> Mar 2015 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: MOMA: Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2015
P2, N=222, Recruiting, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Jun 2015
- || Vectibix (panitumumab) / Amgen
Trial primary completion date, IO biomarker: PULSE: Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2015
P2, N=80, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Jan 2015 --> Jun 2015 Trial primary completion date: Apr 2015 --> Jan 2015
- Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Metastases: BEBYP: Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab (clinicaltrials.gov) - Mar 11, 2015
P3, N=184, Terminated, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial primary completion date: Apr 2015 --> Jan 2015 N=262 --> 184 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2012 --> Feb 2013
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: TRIBE2: Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (clinicaltrials.gov) - Mar 11, 2015
P3, N=654, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
N=262 --> 184 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2012 --> Feb 2013 Not yet recruiting --> Recruiting
- Vectibix (panitumumab) / Amgen
Trial completion, Trial primary completion date: TRIP: FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2015
P2, N=37, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Oct 2011
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 10, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Oct 2011 Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019
- | Xpovio (selinexor) / Karyopharm
New P1 trial, Metastases: SENTINEL: Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2015
P1, N=27, Not yet recruiting, Sponsor: GSO Global Clinical Research BV
- PF-04136309 / Pfizer
Enrollment closed, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 10, 2015
P1, N=44, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019 Recruiting --> Active, not recruiting
- ||||||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: ML18147: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Mar 10, 2015
P3, N=821, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Mar 9, 2015
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Aug 2015
- Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 9, 2015
P3, N=598, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Aug 2015 Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Mar 7, 2015
P3, N=2433, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=3610 --> 2433
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Trial primary completion date, Metastases: Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Mar 7, 2015
P2, N=49, Recruiting, Sponsor: Jilin Provincial Tumor Hospital
N=3610 --> 2433 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial primary completion date: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Mar 5, 2015
P1/2, N=6, Recruiting, Sponsor: Isofol Medical AB
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jul 2015 --> Oct 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Mar 5, 2015
P1/2, N=45, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Jan 2017
- ||||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 5, 2015
P2, N=324, Recruiting, Sponsor: Takeda
- leucovorin calcium / Generic mfg.
Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Mar 3, 2015
P2, N=192, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: Jan 2015 --> Jan 2017 Trial primary completion date: Sep 2015 --> Sep 2017
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (clinicaltrials.gov) - Mar 3, 2015
P2, N=2, Terminated, Sponsor: Western Regional Medical Center
Trial primary completion date: Sep 2015 --> Sep 2017 N=14 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jul 2014; PI Decision
- ||||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Mar 3, 2015
P2, N=100, Recruiting, Sponsor: Fudan University
- Enrollment open: Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers (clinicaltrials.gov) - Mar 3, 2015
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
N=14 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jul 2014; PI Decision Not yet recruiting --> Recruiting
- Trial completion, Metastases: GRECCAR 4: Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma (clinicaltrials.gov) - Mar 3, 2015
P2, N=150, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Mar 2, 2015
P2, N=30, Not yet recruiting, Sponsor: Safi Shadha, M.D.
- ||||||| Trial completion, Metastases: A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 26, 2015
P3, N=480, Completed, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Completed Recruiting --> Completed
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial initiation date: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Feb 25, 2015
P2, N=32, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Initiation date: Jan 2015 --> May 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial withdrawal: BOS3: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (clinicaltrials.gov) - Feb 20, 2015
P2/3, N=0, Withdrawn, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: Jan 2015 --> May 2015 N=240 --> 0 | Not yet recruiting --> Withdrawn
- | conatumumab (AMG 655) / Amgen
Enrollment closed, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 20, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
N=240 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- New P4 trial, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Feb 19, 2015
P4, N=36, Not yet recruiting, Sponsor: University of Chicago
- duligotuzumab (MEHD7945A) / Roche
Trial completion, Trial primary completion date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 19, 2015
P2, N=135, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014
- | New P2 trial, Surgery, Metastases: CAOAROAIO-12: Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Feb 18, 2015
P2, N=304, Not yet recruiting, Sponsor: Prof. Dr. med. Claus R
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Metastases: RIA: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Feb 18, 2015
P2, N=180, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014 Not yet recruiting --> Recruiting
- | New P2 trial: PROTECT: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (clinicaltrials.gov) - Feb 10, 2015
P2, N=106, Recruiting, Sponsor: Centre Oscar Lambret
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Feb 9, 2015
P1, N=95, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Dec 2016
- Metastases: mEGA: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (clinicaltrials.gov) - Feb 9, 2015
P=N/A, N=20, Recruiting, Sponsor: Georgetown University
- ||||||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Surgery: NCCTG N0147: Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (clinicaltrials.gov) - Feb 9, 2015
P3, N=3397, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Dec 2016 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Feb 6, 2015
P1, N=16, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
- Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2015
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- || andecaliximab (GS-5745) / Gilead
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 5, 2015
P1, N=111, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Oct 2015 --> Apr 2016
- PF-04136309 / Pfizer
Trial primary completion date, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 5, 2015
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Feb 2015 --> Oct 2013
- || New P3 trial: GIP-2: Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer (clinicaltrials.gov) - Feb 5, 2015
P3, N=310, Recruiting, Sponsor: Azienda Ospedaliero, Universitaria Pisana
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer (clinicaltrials.gov) - Feb 5, 2015
P2, N=39, Completed, Sponsor: Yale University
Trial primary completion date: Feb 2015 --> Oct 2013 Active, not recruiting --> Completed
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Metastases: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (clinicaltrials.gov) - Feb 2, 2015
P1, N=60, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Jul 2016
- | New P2 trial, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Feb 2, 2015
P2, N=276, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Enrollment closed, Trial primary completion date, Metastases: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Feb 2, 2015
P2, N=45, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jul 2014 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- New P2 trial, Metastases: FLAP: FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 30, 2015
P2, N=50, Completed, Sponsor: Azienda Ospedaliero, Universitaria Pisana
- || Rituxan (rituximab) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial primary completion date: Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=52, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Aug 2014 --> Aug 2015
- ||||| Avastin (bevacizumab) / Roche
New P2 trial, Metastases: FORBES: FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type (clinicaltrials.gov) - Jan 29, 2015
P2, N=138, Recruiting, Sponsor: Sun Yat-sen University
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Metastases: Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) - Jan 28, 2015
P2, N=5, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Aug 2014 --> Aug 2015 N=150 --> 5 | Recruiting --> Terminated; poor accrual